Llwytho...

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation

Imatinib, an ABL tyrosine kinase inhibitor (TKI), has shown clinical efficacy against chronic myeloid leukemia (CML). However, a substantial number of patients develop resistance to imatinib treatment due to the emergence of clones carrying mutations in the protein BCR-ABL. The phosphoinositide 3 ki...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Kitahara, Toshihiko, Kimura, Shinya, Maekawa, Taira, Ohyashiki, Kazuma
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Landes Bioscience 2014
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3928137/
https://ncbi.nlm.nih.gov/pubmed/24100660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.26725
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!